HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife goes private

This article was originally published in The Tan Sheet

Executive Summary

Supplement direct marketer's stock delisted from NASDAQ July 31 upon same-day shareholder approval, completion of $685 mil. transaction to take company private. Holders of approximately 73.9% of all shares of voting common stock gave their consent to the transaction, with stockholders receiving $19.50 per share. Herbalife was acquired by an investor group led by equity firms Whitney & Co. and Golden Gate Capital, in partnership with direct marketer's distributors, senior management. Whitney Chairman & Managing Partner Peter Castleman is new chairman of Herbalife, while Francis Tirelli remains president, CEO. Transaction brings closure to almost three-year effort initiated by late founder Mark Hughes to take the firm private (1"The Tan Sheet" April 15, 2002, p. 5)...

You may also be interested in...

New Herbalife CEO

Michael Johnson succeeds Francis Tirelli as CEO effective April 14, direct marketer announces. Johnson is a 17-year veteran of Walt Disney Corporation, where he most recently served as president of Walt Disney International. Herbalife was taken private July 31 after acquisition by an investor group led by equity firms Whitney & Co., Golden Gate Capital, Herbalife senior management (1"The Tan Sheet" Aug. 5, 2002, In Brief). Tirelli resigned from CEO post in September to pursue other opportunities...

Herbalife Buyout By Equity Groups Achieves Long-Sought Private Ownership

The pending acquisition of Herbalife by equity firms Whitney & Co. and Golden Gate Capital ends a two-and-a-half year effort, initiated by late founder and CEO Mark Hughes, to take the direct marketer private

Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials

Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts